Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab

Tjeerd van der Veer*, Marloes A. Dallinga, Johanna P.M. van der Valk, Jasper H. Kappen, Johannes C.C.M. in ’t Veen, Menno M. van der Eerden, Gert Jan Braunstahl

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorProfessionalpeer-review

9 Citations (Scopus)
50 Downloads (Pure)
Original languageEnglish
Article numbere12081
JournalClinical and Translational Allergy
Issue number10
Publication statusPublished - 3 Dec 2021

Bibliographical note

Funding Information:
Jasper H. Kappen has received grant/research support for consultations and/or speaking at conferences from ALK, Chiesi, GSK, Novartis, ASIT, AstraZeneca, Sanofi, Boerhinger, Teva, Viatris. Johannes C.C.M. in ?t Veen reports to have received institutional grants from Chiesi, TEVA, and Astra Zeneca outside the submitted work and speaker fees from Chiesi, AstraZeneca, and Sanofi Regeneron. Menno M. van der Eerden reports to receive research support from the Chiesi Pharmaceuticals. Gert-Jan Braunstahl reports to have received institutional grants and/or speaker fees from GSK, TEVA, Chiesi and Astra Zeneca outside the submitted work and participated in advisory boards for AstraZeneca, GSK, ALK Abello and Sanofi Regeneron.

Cite this